Amylyx Pharmaceuticals, Inc. — Director's Dealing 2022

Jan 6, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Amylyx Pharmaceuticals, Inc. (AMLX)
CIK: 0001658551
Period of Report: 2022-01-06

Reporting Person: Klee Justin B. (Director, Co-Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2484195	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.37	2023-02-16	Common Stock (334520)		Direct
Stock Option (Right to Buy)	$1.57	2025-02-26	Common Stock (100000)		Direct
Stock Option (Right to Buy)	$7.57	2026-02-19	Common Stock (200000)		Direct
Series C-1 Preferred Stock	$		Common Stock (4870)		Direct

Footnotes

F1: 6,977 shares subject to such stock option vested and became exercisable on March 16, 2018 and the remainder of the shares vest in monthly installments of 6,969 shares for a period of 47 months after the vesting commencement date.

F2: 25,012 shares subject to such option vested and became exercisable on February 26, 2021 and the remainder of the shares vest in monthly installments of 2,083 shares thereafter.

F3: 50,024 shares subject to such option shall vest and become exercisable on February 19, 2022 and the remainder of the shares vest in monthly installments of 4,166 shares thereafter.

F4: Each share of Series C-1 preferred stock is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Series C-1 Preferred stock has no expiration date.